Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone949-261-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$190,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable
Hancock Jaffe Laboratories (NASDAQ:HJLI) Frequently Asked Questions
What is Hancock Jaffe Laboratories' stock symbol?
Hancock Jaffe Laboratories trades on the NASDAQ under the ticker symbol "HJLI."
How were Hancock Jaffe Laboratories' earnings last quarter?
Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) announced its quarterly earnings results on Thursday, October, 31st. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04. View Hancock Jaffe Laboratories' Earnings History.
When is Hancock Jaffe Laboratories' next earnings date?
What price target have analysts set for HJLI?
1 Wall Street analysts have issued 12-month price targets for Hancock Jaffe Laboratories' shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Hancock Jaffe Laboratories' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 328.6% from the stock's current price. View Analyst Price Targets for Hancock Jaffe Laboratories.
What is the consensus analysts' recommendation for Hancock Jaffe Laboratories?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hancock Jaffe Laboratories in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hancock Jaffe Laboratories.
What are Wall Street analysts saying about Hancock Jaffe Laboratories stock?
Here are some recent quotes from research analysts about Hancock Jaffe Laboratories stock:
- 1. Maxim Group analysts commented, "Hancock Jaffe announced positive 90-day results from its animal feasibility for CoreoGraft, its off-the-shelf conduit for Coronary Artery Bypass Grafting (CABG)." (8/15/2019)
- 2. According to Zacks Investment Research, "Hancock Jaffe Laboratories, Inc. is involved in developing and manufacturing bioprosthetic medical devices to treat cardiac and vascular diseases. Its product candidates consists of the porcine tissue based VenoValve, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency; CoreoGraftÒ, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery and a porcine tissue based heart valve, is an ideal candidate for pediatric aortic/mitral valve replacement. Hancock Jaffe Laboratories, Inc. is based in IRVINE, United States. " (6/26/2019)
Has Hancock Jaffe Laboratories been receiving favorable news coverage?
News stories about HJLI stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hancock Jaffe Laboratories earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Hancock Jaffe Laboratories.
Are investors shorting Hancock Jaffe Laboratories?
Hancock Jaffe Laboratories saw a drop in short interest in January. As of January 31st, there was short interest totalling 146,700 shares, a drop of 20.1% from the January 15th total of 183,600 shares. Based on an average trading volume of 74,300 shares, the short-interest ratio is presently 2.0 days. Currently, 1.2% of the company's shares are short sold. View Hancock Jaffe Laboratories' Current Options Chain.
Who are some of Hancock Jaffe Laboratories' key competitors?
Some companies that are related to Hancock Jaffe Laboratories include Delcath Systems (DCTH), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Interpace Diagnostics Group (IDXG), T2 Biosystems (TTOO), Neovasc (NVCN), Biostage (BSTG), RA Medical Systems (RMED), DarioHealth (DRIO), Titan Medical (TMDI), Endologix (ELGX), Obalon Therapeutics (OBLN), Lianluo Smart (LLIT), Atossa Genetics (ATOS) and Avinger (AVGR).
What other stocks do shareholders of Hancock Jaffe Laboratories own?
Who are Hancock Jaffe Laboratories' key executives?
Hancock Jaffe Laboratories' management team includes the folowing people:
- Mr. Robert A. Berman, CEO & Director (Age 56)
- Mr. Robert Rankin, CFO, Sec. & Treasurer (Age 66)
- Dr. Benedict Broennimann M.D., Chief Medical Officer of Outside of United States (Age 62)
- Dr. Marc H. Glickman, Sr. VP & Chief Medical Officer (Age 70)
- Mr. Warren Hancock, Co-founder
When did Hancock Jaffe Laboratories IPO?
(HJLI) raised $8 million in an IPO on Thursday, May 31st 2018. The company issued 1,500,000 shares at $5.00 per share. Network 1 Financial Securities served as the underwriter for the IPO and ViewTrade Securities was co-manager.
Who are Hancock Jaffe Laboratories' major shareholders?
Which major investors are selling Hancock Jaffe Laboratories stock?
How do I buy shares of Hancock Jaffe Laboratories?
Shares of HJLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Hancock Jaffe Laboratories' stock price today?
One share of HJLI stock can currently be purchased for approximately $0.70.
How big of a company is Hancock Jaffe Laboratories?
What is Hancock Jaffe Laboratories' official website?
How can I contact Hancock Jaffe Laboratories?
Hancock Jaffe Laboratories' mailing address is 70 DOPPLER, IRVINE CA, 92618. The company can be reached via phone at 949-261-2900.
MarketBeat Community Rating for Hancock Jaffe Laboratories (NASDAQ HJLI)
MarketBeat's community ratings are surveys of what our community members think about Hancock Jaffe Laboratories and other stocks. Vote "Outperform" if you believe HJLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HJLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
